GlassScriptPhysician profile
Maria Tedi C Coronel
NPI 1558848218
$19,052.55
in general payments reported to CMS, 2019-2025
36 companies · $4,336 in 2025
The $4,336 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $2,614 · 2023: $6,746 · 2024: $4,428 · 2025: $4,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $2,640 · Travel and Lodging: $774 · Education: $553 · Consulting Fee: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,073.49 |
| Honoraria | $2,640.00 |
| Travel and Lodging | $773.75 |
| Education | $553.38 |
| Consulting Fee | $470.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,847.11 | 2022-2023 | Uplizna |
| Emd Serono, INC. | $3,279.01 | 2021-2024 | Mavenclad |
| Biogen, INC. | $2,074.40 | 2021-2025 | Tysabri, Vumerity, Tysabri |
| Janssen Biotech, INC. | $962.14 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $915.18 | 2021-2024 | Zeposia |
| Abbvie INC. | $827.74 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $629.82 | 2022-2025 | Ultomiris, Soliris |
| Janssen Scientific Affairs, LLC | $544.69 | 2024-2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $541.80 | 2021-2023 | Ponvory |
| E.R. Squibb & Sons, L.L.C. | $537.87 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $474.66 | 2023-2024 | |
| Amgen INC. | $469.37 | 2024-2025 | Repatha, Uplizna |
| Genzyme Corporation | $402.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $382.23 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Tg Therapeutics, INC. | $377.45 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $339.68 | 2021-2025 | Omvoh, Emgality, Reyvow |
| Genentech USA, INC. | $309.85 | 2022-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $275.79 | 2022-2024 | Ajovy, Austedo Xr |
| Novo Nordisk INC | $180.99 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $177.78 | 2021-2023 | Andexxa |
| Ipsen Biopharmaceuticals, INC | $160.08 | 2025 | Iqirvo |
| Lundbeck LLC | $147.42 | 2022-2024 | Vyepti |
| Celltrion USA INC. | $143.97 | 2025 | Vegzelma |
| Medtronic, INC. | $143.34 | 2024 | Synchromedii |
| Biohaven Pharmaceutical Holding Company LTD. | $134.96 | 2022 | |
| Gilead Sciences, INC. | $131.40 | 2025 | Livdelzi |
| Vanda Pharmaceuticals INC. | $124.98 | 2024 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $121.19 | 2023 | Nuedexta |
| Phathom Pharmaceuticals, INC. | $118.39 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $117.88 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.82 | 2025 | Xifaxan |
| Pfizer INC. | $32.63 | 2025 | |
| Axonics, INC. | $18.70 | 2024 | Bulkamid, Axonics |
| Harmony Biosciences LLC | $18.47 | 2024 | |
| Sk Life Science, INC. | $17.62 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Tedi Coronel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.